IONIS PHARMACEUTICALS INC (IONS) Fundamental Analysis & Valuation

NASDAQ:IONS • US4622221004

71.19 USD
-1.15 (-1.59%)
At close: Mar 13, 2026
71.19 USD
0 (0%)
After Hours: 3/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IONS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IONS. IONS was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of IONS have multiple concerns. IONS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. IONS Profitability Analysis

1.1 Basic Checks

  • In the past year IONS has reported negative net income.
  • In the past year IONS has reported a negative cash flow from operations.
  • IONS had negative earnings in each of the past 5 years.
  • In the past 5 years IONS reported 4 times negative operating cash flow.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

1.2 Ratios

  • IONS's Return On Assets of -10.82% is amongst the best of the industry. IONS outperforms 82.66% of its industry peers.
  • IONS has a Return On Equity (-77.98%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -10.82%
ROE -77.98%
ROIC N/A
ROA(3y)-12.73%
ROA(5y)-9.98%
ROE(3y)-83.28%
ROE(5y)-60.13%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • Looking at the Gross Margin, with a value of 98.31%, IONS belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
  • IONS's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for IONS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.01%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IONS Health Analysis

2.1 Basic Checks

  • IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IONS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IONS has been increased compared to 5 years ago.
  • IONS has a worse debt/assets ratio than last year.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 1.98 indicates that IONS is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • IONS has a better Altman-Z score (1.98) than 65.13% of its industry peers.
  • IONS has a Debt/Equity ratio of 3.88. This is a high value indicating a heavy dependency on external financing.
  • IONS's Debt to Equity ratio of 3.88 is on the low side compared to the rest of the industry. IONS is outperformed by 80.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.88
Debt/FCF N/A
Altman-Z 1.98
ROIC/WACCN/A
WACC8.05%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.83 indicates that IONS has no problem at all paying its short term obligations.
  • IONS has a Current ratio of 3.83. This is comparable to the rest of the industry: IONS outperforms 44.89% of its industry peers.
  • IONS has a Quick Ratio of 3.81. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
  • IONS has a Quick ratio (3.81) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.81
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. IONS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 19.74% over the past year.
  • The Revenue has grown by 33.83% in the past year. This is a very strong growth!
  • IONS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.29% yearly.
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-113.64%
Revenue 1Y (TTM)33.83%
Revenue growth 3Y17.12%
Revenue growth 5Y5.29%
Sales Q2Q%-10.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.01% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, IONS will show a very strong growth in Revenue. The Revenue will grow by 31.23% on average per year.
EPS Next Y-58.89%
EPS Next 2Y17.73%
EPS Next 3Y30.13%
EPS Next 5Y36.01%
Revenue Next Year-6.89%
Revenue Next 2Y24.48%
Revenue Next 3Y27.37%
Revenue Next 5Y31.23%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. IONS Valuation Analysis

4.1 Price/Earnings Ratio

  • IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IONS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • IONS's earnings are expected to grow with 30.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.73%
EPS Next 3Y30.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IONS Dividend Analysis

5.1 Amount

  • IONS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IONS Fundamentals: All Metrics, Ratios and Statistics

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (3/13/2026, 8:00:02 PM)

After market: 71.19 0 (0%)

71.19

-1.15 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners105.44%
Inst Owner Change-16.47%
Ins Owners0.82%
Ins Owner Change-0.91%
Market Cap11.76B
Revenue(TTM)943.71M
Net Income(TTM)-381.39M
Analysts81.38
Price Target92.16 (29.46%)
Short Float %9.65%
Short Ratio7.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.89%
Min EPS beat(2)-4.63%
Max EPS beat(2)36.42%
EPS beat(4)3
Avg EPS beat(4)77.43%
Min EPS beat(4)-4.63%
Max EPS beat(4)259.57%
EPS beat(8)7
Avg EPS beat(8)54.04%
EPS beat(12)11
Avg EPS beat(12)47.44%
EPS beat(16)13
Avg EPS beat(16)37.6%
Revenue beat(2)2
Avg Revenue beat(2)22.53%
Min Revenue beat(2)17.57%
Max Revenue beat(2)27.5%
Revenue beat(4)4
Avg Revenue beat(4)24.62%
Min Revenue beat(4)3.26%
Max Revenue beat(4)50.14%
Revenue beat(8)7
Avg Revenue beat(8)24.27%
Revenue beat(12)11
Avg Revenue beat(12)26.31%
Revenue beat(16)13
Avg Revenue beat(16)20.18%
PT rev (1m)1.12%
PT rev (3m)7.66%
EPS NQ rev (1m)-16.23%
EPS NQ rev (3m)-10.88%
EPS NY rev (1m)-24.02%
EPS NY rev (3m)-26.82%
Revenue NQ rev (1m)-0.76%
Revenue NQ rev (3m)3.52%
Revenue NY rev (1m)-7.27%
Revenue NY rev (3m)-8.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.46
P/FCF N/A
P/OCF N/A
P/B 24.04
P/tB 24.04
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-3.88
Fwd EYN/A
FCF(TTM)-1.94
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS5.71
BVpS2.96
TBVpS2.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.82%
ROE -77.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.31%
FCFM N/A
ROA(3y)-12.73%
ROA(5y)-9.98%
ROE(3y)-83.28%
ROE(5y)-60.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.01%
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 3.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 413.3%
Cap/Sales 5.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.83
Quick Ratio 3.81
Altman-Z 1.98
F-Score4
WACC8.05%
ROIC/WACCN/A
Cap/Depr(3y)325.82%
Cap/Depr(5y)227.7%
Cap/Sales(3y)4.96%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-113.64%
EPS Next Y-58.89%
EPS Next 2Y17.73%
EPS Next 3Y30.13%
EPS Next 5Y36.01%
Revenue 1Y (TTM)33.83%
Revenue growth 3Y17.12%
Revenue growth 5Y5.29%
Sales Q2Q%-10.57%
Revenue Next Year-6.89%
Revenue Next 2Y24.48%
Revenue Next 3Y27.37%
Revenue Next 5Y31.23%
EBIT growth 1Y19.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.51%
EBIT Next 3Y-2.27%
EBIT Next 5YN/A
FCF growth 1Y41.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.38%
OCF growth 3YN/A
OCF growth 5YN/A

IONIS PHARMACEUTICALS INC / IONS FAQ

What is the fundamental rating for IONS stock?

ChartMill assigns a fundamental rating of 3 / 10 to IONS.


What is the valuation status of IONIS PHARMACEUTICALS INC (IONS) stock?

ChartMill assigns a valuation rating of 1 / 10 to IONIS PHARMACEUTICALS INC (IONS). This can be considered as Overvalued.


What is the profitability of IONS stock?

IONIS PHARMACEUTICALS INC (IONS) has a profitability rating of 2 / 10.


What is the financial health of IONIS PHARMACEUTICALS INC (IONS) stock?

The financial health rating of IONIS PHARMACEUTICALS INC (IONS) is 3 / 10.